Artica Therapeutics uses covalent chemistry to develop orally bioavailable small‑molecule inhibitors that achieve antibody‑like potency and selectivity for autoimmune and inflammatory diseases. By forming irreversible bonds with disease‑relevant proteins, its “insurmountable” drugs maintain target engagement even under high stimulation, offering a convenient oral alternative to injectable biologics.

Azafaros develops therapeutic agents that target rare metabolic disorders through metabolic pathway modulation and advanced drug discovery techniques. The company provides effective treatment options for patients with unmet medical needs in this specialized healthcare segment.

Coave Therapeutics develops targeted gene therapies using its proprietary ALIGATER™ platform, which creates ligand‑conjugated AAV vectors that bind selectively to ocular tissues such as the suprachoroidal space. This technology enables highly specific, safer delivery of therapeutic genes for retinal vascular diseases like neovascular age‑related macular degeneration and diabetic macular edema, aiming to provide durable, injection‑free treatments. The modular platform can be applied to other vectors and disease areas, offering pharmaceutical and biotech partners a plug‑and‑play solution for precise gene therapy delivery.

Complement Therapeutics develops novel therapies that modulate the complement system to address unmet needs in complement‑mediated diseases, most notably geographic atrophy in age‑related macular degeneration. Its pipeline includes an AAV‑based gene therapy (CTx001) for retinal complement dysregulation and protein‑based candidates for systemic conditions, supported by a mass‑spectrometry platform that quantifies multiple complement proteins from a single blood sample for patient stratification and trial monitoring.

Deciphex utilizes digital pathology and artificial intelligence to enhance the efficiency and quality of pathology reporting, addressing the increasing demand for pathology services amid a declining number of pathologists. By optimizing workflows and triaging low-complexity samples, Deciphex enables pathologists to focus on more challenging cases, ultimately improving patient care and accelerating drug development.

Loci Orthopaedics develops evidence‑based extremity orthopaedic technologies, including the InDx thumb base joint replacement that replicates natural thumb motion with a dual‑axis, six‑degree‑of‑freedom design. The implant is engineered to preserve hand strength, reduce postoperative pain, and provide a joint‑preserving option for patients with severe thumb base arthritis, targeting hand surgeons and orthopaedic specialists.

The startup provides a modular medical imaging platform that uses a high‑sensitivity CMOS sensor and AI‑enhanced reconstruction to deliver ultra‑high‑definition, multi‑spectral images with reduced radiation dose. The hardware mounts onto existing X‑ray, CT, or ultrasound systems and outputs DICOM‑compatible data for PACS or cloud analytics, improving diagnostic confidence for radiology departments and research labs.

Palliare manufactures surgical smoke evacuation and insufflation technologies, including the EVA15 insufflator, which provides hands-free control and consistent pressure during laparoscopic and endoscopic procedures. This technology addresses the need for effective smoke management and pressure regulation in minimally invasive surgeries, enhancing safety and operational efficiency.

Perfuze is developing a superbore aspiration catheter designed for efficient access to occluded brain arteries during acute ischemic stroke treatment, enhancing the potential for complete clot removal. This technology addresses the significant challenge of achieving positive clinical outcomes, as less than 50% of stroke patients currently benefit from existing therapies.

Quanta Dialysis Technologies provides an FDA‑cleared hemodialysis platform that supports home, in‑center, SLED, and CRRT treatments on a single compact device. By generating dialysate on demand, it eliminates disposable bags, daily rinses, and chemical disinfection, reducing waste and maintenance while simplifying setup across hospitals, dialysis centers, and home‑care settings.

The startup develops therapies targeting the sympathetic nervous system to alleviate symptoms in patients with chronic bronchitis and emphysema. By reducing the impact of chronic obstructive pulmonary disease, the company enables patients to breathe more easily and improve their quality of life.

ShiraTronics develops a neuromodulation device that is implanted beneath the skin to provide continuous stimulation to specific nerves associated with chronic migraine. This technology aims to reduce the frequency and severity of migraine attacks for individuals who do not find relief through traditional medications.

Shorla Oncology develops targeted therapies using proprietary drug formulations specifically designed for women's and pediatric cancers, enhancing treatment efficacy in these populations. The company provides life-saving therapeutic options for patients with limited alternatives in underserved cancer demographics.

Sibylla Biotech develops small molecule folding interfering degraders (FIDs) using its proprietary Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) platform, which employs computer simulations and AI to induce the degradation of target proteins. This approach targets proteins involved in various diseases, addressing the need for new therapeutics in multiple therapeutic areas.

STORM Therapeutics is developing first-in-class small molecule therapies that target RNA modifying enzymes (RME) to create novel cancer treatments. By focusing on over 150 RNA modifications and approximately 300 RNA modifying enzymes, the company aims to address the limitations of current cancer therapies.

Vico Therapeutics develops RNA modulation therapies using antisense oligonucleotides to target genetic neurological disorders, specifically focusing on conditions like Huntington's disease and spinocerebellar ataxia. Their VICOMER™ platform enables allele-preferential targeting of CAG repeat expansions, providing a reversible and transient treatment approach without altering DNA.